Drugs Made In America Acquisition Corp. Rights (DMAAR)
Market Open
26 Oct, 05:56 PM
NASDAQ (NMS) NASDAQ (NMS) Primary $
0. 09
-0.01
-8.4%
$
264.01M Market Cap
- P/E Ratio
- Div Yield
100 Volume
- Eps
$ 0.1
Previous Close Want to track DMAAR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Drugs Made In America Acquisition Corp. Rights Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DB David Barlow Glazer Capital LLC | 297,475 | $38,671.75 | $29,003.81 | -$9,667.94 | -25% |
| MB Mitchel Bialek Css LLC/IL | 31,250 | $6,793.75 | $3,046.87 | -$3,746.88 | -55.15% |
| SK Steven Katznelson Radcliffe Capital Management LP | 143,911 | $31,286.25 | $13,743.5 | -$17,542.75 | -56.07% |
| VL Vincent Leva Linden Advisors LP | 850,000 | $184,790 | $81,175 | -$103,615 | -56.07% |
| CW CaSaundra Wu Westchester Capital Management LLC | 500,000 | $62,450 | $54,750 | -$7,700 | -12.33% |
| WTD Ward T. Dietrich Mangrove Partners Im LLC | 850,000 | $110,500 | $81,175 | -$29,325 | -26.54% |
| BO Brian Oliveira Clear Street Group Inc. | 711,088 | $141,013.07 | $67,908.9 | -$73,104.17 | -51.84% |
2026 © Marketlog. All Rights Reserved.
